Wide Ranks

DCTH

Delcath Systems, Inc.

11.22

Top Statistics
Market Cap 358 M Forward PE -53.43 Revenue Growth 1468.90 %
Current Ratio 2.56 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -8.57 Enterprise / Revenue 25.91 Price To Sales Trailing12 Months 30.20
Profitability
Profit Margins 0.00 % Operating Margins -50.37 %
Balance Sheet
Total Cash 19 M Total Cash Per Share 0.7110 Total Debt 5 M
Total Debt To Equity 27.91 Current Ratio 2.56 Book Value Per Share 0.6930
All Measures
Short Ratio 526.00 % Message Board Id finmb_598622 Fax 212 489 2102
Shares Short Prior Month 1 M Return On Equity -4.79 City New York
Uuid e634292b-7b25-3cd1-9b6a-45d8a0075f17 Previous Close 10.65 First Trade Date Epoch Utc 1 B
Book Value 0.6930 Beta 0.7600 Total Debt 5 M
Volume 474427 Price To Book 16.19 Last Split Date 1 B
Fifty Two Week Low 2.60 Total Cash Per Share 0.7110 Total Revenue 11 M
Shares Short Previous Month Date 1 B Target Median Price 21.50 Max Age 86400
Sand P52 Week Change 0.3133 Operating Margins -50.37 % Target Mean Price 21.33
Net Income To Common -56328000 Short Percent Of Float 0.0446 Implied Shares Outstanding 31 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 476520
Average Volume10days 476520 Total Cash 19 M Next Fiscal Year End 1 B
Revenue Per Share 0.5050 Held Percent Insiders 0.0271 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 10.65
Target Low Price 18.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 9.77
Open 10.61 Free Cashflow -16644625 State NY
Dividend Yield 0.00 % Return On Assets -0.8199 Time Zone Short Name EST
Trailing Eps -1.17 Day Low 10.61 Address1 1633 Broadway
Shares Outstanding 31 M Price Hint 2 Target High Price 25.00
Website https://www.delcath.com 52 Week Change 3.08 Average Volume 359834
Forward Eps -0.3200 Recommendation Key none Compensation As Of Epoch Date 1 B
Quick Ratio 192.50 % Last Split Factor 1:700 Regular Market Day High 11.28
Is_sp_500 False Profit Margins 0.00 % Debt To Equity 27.91
Fifty Two Week High 12.88 Day High 11.28 Shares Short 1 M
Regular Market Open 10.61 Industry Key medical-devices Earnings Growth 0.00 %
Enterprise To Revenue 25.91 Revenue Growth 1468.90 % Shares Percent Shares Out 0.0446
Operating Cashflow -31374000 Currency USD Time Zone Full Name America/New_York
Market Cap 358 M Is_nasdaq_100 False Zip 10019
Quote Type EQUITY Industry Medical Devices Long Name Delcath Systems, Inc.
Regular Market Day Low 10.61 Held Percent Institutions 0.3813 Current Price 11.22
Address2 22nd Floor Suite C Enterprise To Ebitda -8.57 Financial Currency USD
Current Ratio 2.56 Gross Margins 77.05 % Industry Disp Medical Devices
Number Of Analyst Opinions 6 Country United States Float Shares 20 M
Two Hundred Day Average 7.52 Ir Website http://www.delcath.com/investors/ Enterprise Value 307 M
Price To Sales Trailing12 Months 30.20 Forward PE -53.43 Regular Market Volume 474427
Ebitda -35919000 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe.

The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma.

It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe.

Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.